BR112019024264A2 - Antimitoscinas: inibidores direcionados da biogênese mitoconcrial para erradicação de células-tronco de câncer - Google Patents

Antimitoscinas: inibidores direcionados da biogênese mitoconcrial para erradicação de células-tronco de câncer Download PDF

Info

Publication number
BR112019024264A2
BR112019024264A2 BR112019024264-3A BR112019024264A BR112019024264A2 BR 112019024264 A2 BR112019024264 A2 BR 112019024264A2 BR 112019024264 A BR112019024264 A BR 112019024264A BR 112019024264 A2 BR112019024264 A2 BR 112019024264A2
Authority
BR
Brazil
Prior art keywords
antimitoscines
stem cells
cancer stem
mitoconcrial
eradication
Prior art date
Application number
BR112019024264-3A
Other languages
English (en)
Inventor
P. LISANTI Michael
Sotgia Federica
Original Assignee
Lunella Biotech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lunella Biotech, Inc. filed Critical Lunella Biotech, Inc.
Publication of BR112019024264A2 publication Critical patent/BR112019024264A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70585—CD44

Abstract

a presente invenção refere-se a antibióticos que têm propriedades antimitocondriais intrínsecas que podem ser modificados quimicamente para direcionar antibióticos a mitocôndrias, e as "antimitoscinas" resultantes podem ter propriedades anticâncer reforçadas, dentre outras propriedades vantajosas. são descritos também métodos para identificação de antimitoscinas, métodos para utilização de antimitoscinas para direcionar a células-tronco de câncer e composições farmacêuticas para tratar câncer que contém uma ou mais antimitoscinas como o ingrediente ativo. compostos específicos antimitoscinas e grupos de antimitoscinas são também descritos.
BR112019024264-3A 2017-05-19 2018-05-18 Antimitoscinas: inibidores direcionados da biogênese mitoconcrial para erradicação de células-tronco de câncer BR112019024264A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762508702P 2017-05-19 2017-05-19
US62/508,702 2017-05-19
PCT/US2018/033466 WO2018213751A1 (en) 2017-05-19 2018-05-18 Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells

Publications (1)

Publication Number Publication Date
BR112019024264A2 true BR112019024264A2 (pt) 2020-06-02

Family

ID=64274780

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019024264-3A BR112019024264A2 (pt) 2017-05-19 2018-05-18 Antimitoscinas: inibidores direcionados da biogênese mitoconcrial para erradicação de células-tronco de câncer

Country Status (20)

Country Link
US (2) US11160821B2 (pt)
EP (1) EP3624840A4 (pt)
JP (1) JP6938682B2 (pt)
KR (1) KR20200010343A (pt)
CN (1) CN111315400A (pt)
AU (1) AU2018270129B2 (pt)
BR (1) BR112019024264A2 (pt)
CA (1) CA3063717C (pt)
CL (1) CL2019003283A1 (pt)
CO (1) CO2019012888A2 (pt)
CR (1) CR20190524A (pt)
CU (1) CU20190092A7 (pt)
DO (1) DOP2019000294A (pt)
EC (1) ECSP19082194A (pt)
IL (1) IL270598B (pt)
MX (1) MX2019013735A (pt)
PE (1) PE20200605A1 (pt)
RU (1) RU2019142102A (pt)
WO (1) WO2018213751A1 (pt)
ZA (3) ZA201907654B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3060510A1 (en) 2017-04-21 2018-10-25 Lunella Biotech, Inc. Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
US11229657B2 (en) 2017-04-21 2022-01-25 Lunella Biotech, Inc. Targeting hypoxic cancer stem cells (CSCs) with doxycycline: implications for improving anti-angiogenic therapy
BR112019024264A2 (pt) 2017-05-19 2020-06-02 Lunella Biotech, Inc. Antimitoscinas: inibidores direcionados da biogênese mitoconcrial para erradicação de células-tronco de câncer
CR20200033A (es) 2017-06-26 2020-03-05 Lunella Biotech Inc Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosas
EP3695005B1 (en) 2017-10-11 2023-12-06 Lunella Biotech, Inc. Anti-mitochondrial inhibitors for oncogenic ras and myc
WO2019108729A1 (en) * 2017-12-01 2019-06-06 Lunella Biotech, Inc. Repurposcins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
CA3114888A1 (en) 2018-10-02 2020-04-09 Lunella Biotech, Inc. Azithromycin and roxithromycin derivatives as senolytic drugs
KR20210104829A (ko) * 2018-12-17 2021-08-25 루넬라 바이오테크 인코포레이티드 미토콘드리아를 표적화하고 암 줄기 세포를 사멸시키는 삼중 조합 요법
PE20220499A1 (es) * 2018-12-17 2022-04-07 Lunella Biotech Inc Terapias de combinacion triple para anti-envejecimiento
EP3976197A4 (en) * 2019-05-24 2023-07-19 Lunella Biotech, Inc. THERAPEUTIC AGENTS AND METHODS FOR PREDICTING AND OVERCOMING ENDOCRINE RESISTANCE IN BREAST CANCER
CN114173773A (zh) * 2019-06-26 2022-03-11 卢内拉生物技术有限公司 用于靶向线粒体和根除癌症干细胞的碳菁化合物
WO2021081500A1 (en) 2019-10-24 2021-04-29 The Medical College Of Wisconsin, Inc. Mitochondria-targeted atovaquone: a more potent and more effective antitumor, antimicrobial, and antimalarial drug
US20240010622A1 (en) * 2020-10-22 2024-01-11 Lunella Biotech, Inc. Mitochondrial atp inhibitors targeting the gamma subunit prevent metastasis

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2862921A (en) * 1953-08-13 1958-12-02 Upjohn Co Erythromycin esters
US3517067A (en) 1964-02-11 1970-06-23 Eastman Kodak Co Syntheses of quaternary phosphonium salts
DK149776C (da) 1984-01-06 1987-04-21 Orion Yhtymae Oy Antibiotisk virksom erytromycinforbindelse og praeparat indeholdende forbindelsen
EP0310361A3 (en) 1987-09-30 1989-05-24 Beckman Instruments, Inc. Tridentate conjugate and method of use thereof
SI9011409A (en) 1990-07-18 1995-10-31 Pliva Pharm & Chem Works O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them
EP0656422B1 (en) 1993-11-05 2000-04-26 Amersham Pharmacia Biotech UK Limited Chloramphenicol acetyl transferase (CAT) assay
WO1995015770A1 (en) 1993-12-09 1995-06-15 Neorx Corporation Pretargeting methods and compounds
US5441939A (en) 1994-03-04 1995-08-15 Pfizer Inc. 3"-desmethoxy derivatives of erythromycin and azithromycin
US5795871A (en) 1994-04-26 1998-08-18 Nobuhiro Narita Pharmaceutical composition for treatment of non-small cell lung cancer
WO1996034852A1 (en) 1995-05-03 1996-11-07 Pfizer, Inc. Novel tetracycline derivatives
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5837696A (en) 1997-01-15 1998-11-17 The Research Foundation Of State University Of New York Method of inhibiting cancer growth
ATE296305T1 (de) 1997-11-25 2005-06-15 Antipodean Biotechnology Ltd Antioxidantien mit spezifischer wirkung auf mitochondrien
ATE275151T1 (de) 1998-03-03 2004-09-15 Pfizer Prod Inc 3,6-ketal-makrolidantibiotika
AUPP437698A0 (en) 1998-06-30 1998-07-23 Baumgart, Karl Methods for treatment of coronary, carotid and other vascular disease
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
EP1461084A2 (en) * 2001-12-11 2004-09-29 The Board Of Trustees Of The Leland Stanford Junior University Guanidinium transport reagents and conjugates
US7485298B2 (en) 2002-05-23 2009-02-03 Michael Powell Diagnosis and treatment of human dormancy-related sequellae
RU2223103C1 (ru) 2002-07-17 2004-02-10 Открытое акционерное общество "Биосинтез" Фармацевтическая композиция, обладающая антибактериальным действием
NZ541846A (en) 2003-01-27 2008-12-24 Endocyte Inc Vitamin receptor binding drug delivery conjugates
WO2005062851A2 (en) 2003-12-22 2005-07-14 Pappolla Miguel A Indole-3-propionamide and derivatives thereof
TWI297606B (en) 2004-01-16 2008-06-11 Nat Health Research Institutes Cancer therapy
EP1720555A1 (en) 2004-02-26 2006-11-15 Advanced Ocular Systems Limited Tetracycline derivatives for the treatment of ocular pathologies
US20060083727A1 (en) 2004-07-15 2006-04-20 Nanobac Pharmaceuticals, Inc. Methods and compositions for the treatment of diseases characterized by calcification and/or plaque formation
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
ATE523519T1 (de) 2005-01-14 2011-09-15 Glaxo Group Ltd Makrolidverbindungen mit biotin und fotoaffinitätsgruppe zur identifizierung eines makrolid-targets
CN1706391A (zh) 2005-05-09 2005-12-14 史同瑞 土霉素混悬乳剂
JP5177429B2 (ja) 2005-07-18 2013-04-03 バイパー サイエンシズ，インコーポレイティド 癌の治療
CN1837229A (zh) 2005-08-05 2006-09-27 济南思创生物技术有限公司 克拉霉素衍生物及其制备方法和药物应用
DE102005039579B4 (de) 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
CN1837225A (zh) 2005-08-23 2006-09-27 济南思创生物技术有限公司 阿奇霉素衍生物及其制法和药物应用
EP2094268A2 (en) 2006-05-26 2009-09-02 Bayer HealthCare, LLC Drug combinations with substituted diaryl ureas for the treatment of cancer
JP2009539769A (ja) 2006-06-02 2009-11-19 アリアド ジーン セラピューティクス インコーポレイテッド カペシタビン併用療法
US20080118432A1 (en) 2006-09-07 2008-05-22 Ivan Bergstein Monitoring cancer stem cells
AU2007314366A1 (en) 2006-10-30 2008-05-08 Southern Research Institute Targeting NBS1-ATM interaction to sensitize cancer cells to radiotherapy and chemotherapy
JP5933893B2 (ja) 2006-12-14 2016-06-15 アブラクシス バイオサイエンス， エルエルシー ホルモン受容体状態に基づいてタキサンを含むナノ粒子用いる乳癌治療法
US8075902B2 (en) 2007-01-03 2011-12-13 Michael Powell Diagnosis and treatment of cancer related to human dormancy
DE102007025423A1 (de) 2007-05-30 2008-12-04 Friedrich-Schiller-Universität Jena Triphenylphosphonium-Derivate zum gezielten Transport und Freisetzen von Substanzen in Mitochondrien sowie Verfahren zu deren Verwendung
US20090099062A1 (en) 2007-05-31 2009-04-16 Ethan Lee Pyrvinium For The Treatment of Cancer
WO2009015214A2 (en) 2007-07-24 2009-01-29 Wayne State University Nanoparticles for imaging and treating chlamydial infection
EP2200653A2 (en) * 2007-09-10 2010-06-30 University of Massachusetts Mitochondria-targeted anti-tumour agents
WO2009038656A1 (en) 2007-09-17 2009-03-26 Kosta Steliou Mitochondria-targeting antioxidant therapeutics
EP2188630A4 (en) 2007-10-02 2010-11-03 Univ Rochester METHODS AND COMPOSITIONS ASSOCIATED WITH SYNERGIC RESPONSES TO ONCOGENIC MUTATIONS
US20100297262A1 (en) 2009-04-17 2010-11-25 Colby Pharmaceutical Company Pharmaceutically active compositions comprising oxidative stress modulators (osm), new chemical entities, compositions and uses
GB0912584D0 (en) 2009-07-20 2009-08-26 Ucl Business Plc Cyclosporin conjugates
CA2772120A1 (en) 2009-08-25 2011-03-17 President And Fellows Of Harvard College Use of metformin in cancer treatment and prevention
EP2338476B1 (en) * 2009-12-02 2012-06-20 Bettina Heil Suppository for rectal, vaginal or urethral administration containing a probiotic, an antibiotic and an unsaturated non-esterified fatty acid
CN109224064A (zh) 2009-12-04 2019-01-18 昂科免疫有限公司 低氧诱导因子抑制剂的用途
WO2011109899A1 (en) 2010-03-10 2011-09-15 University Health Network Use of tigecycline for treatment of cancer
CN101810570B (zh) * 2010-04-16 2012-06-20 成都师创生物医药科技有限公司 蒽环类抗肿瘤抗生素脂肪酸复合物脂质纳米粒制剂及其制备方法
WO2011133879A2 (en) * 2010-04-22 2011-10-27 University Of Massachusetts Combination therapies with mitochondrial-targeted anti-tumor agents
US20120141467A1 (en) 2010-12-03 2012-06-07 Schneider Daniel J Ascorbic acid to treat chronic obstructive lung diseases and non-Hodgkin's lymphoma
JP6486004B2 (ja) 2011-02-10 2019-03-20 ルプレヒト−カールス−ウニヴェルジテート ハイデルベルクＲｕｐｒｅｃｈｔ−Ｋａｒｌｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｈｅｉｄｅｌｂｅｒｇ 疎水性修飾ペプチドおよび肝臓特異的標的化のためのその使用
CN103857440B (zh) 2011-06-22 2018-09-25 维奥姆生物科学有限公司 基于缀合物的抗真菌和抗细菌前药
EP3111937B1 (en) 2011-07-08 2020-06-17 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for treatment of liver cancer
US9801922B2 (en) 2011-08-03 2017-10-31 University Of Iowa Research Foundation Compositions and methods of treating cancer
CN102911226B (zh) * 2011-08-03 2015-11-25 胡梨芳 硬脂酸红霉素类化合物物实体及其用途
US9180134B2 (en) 2011-08-18 2015-11-10 Ecole Polytechnique Federale De Lausanne (Epel) Mitochondrial ribosomal proteins as aging regulators
WO2013040206A1 (en) 2011-09-14 2013-03-21 Lewis Thomas J Novel formulations comprising macrolide and tetracycline and their uses
EP2819993B1 (en) 2012-03-01 2020-09-02 University Of Cincinnati Ros-activated compounds as selective anti-cancer therapeutics
US9526795B2 (en) 2012-08-28 2016-12-27 Annam Biosciences, Llc N-BOC-dendrimers and their conjugates
US20150224169A1 (en) 2012-09-06 2015-08-13 Mcmaster University Compounds and methods for selectively targeting cancer stem cells
US20140106004A1 (en) 2012-10-12 2014-04-17 Bing Lou Wong Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence
US9636329B2 (en) 2012-11-06 2017-05-02 Northwestern University Methods of treating cancer with glut inhibitors and oxidative phosphorylation inhibitors
CN105142631A (zh) 2013-01-14 2015-12-09 健康诊所有限公司 抗癌药物和用途
WO2014138338A1 (en) 2013-03-06 2014-09-12 The General Hospital Corporation Combinatorial compositions and methods for treatment of melanoma
EA029881B1 (ru) 2013-04-24 2018-05-31 Смарт Брейн С.Р.О. Производные тамоксифена для лечения новообразований, особенно с высоким уровнем белка her2
WO2015002996A1 (en) 2013-07-01 2015-01-08 University Of Georgia Research Foundation, Inc. Precise delivery of therapeutic agents to cell mitochondria for anti-cancer therapy
WO2015050844A1 (en) 2013-10-01 2015-04-09 Dana-Farber Cancer Institute, Inc. Methods of treating cancer with atovaquone-related compounds
CN103536530A (zh) 2013-10-30 2014-01-29 王玉万 盐酸多西环素长效注射剂及制备方法
CA2843943A1 (en) 2014-02-20 2014-05-28 Pankaj Modi Oral formulations of chemotherapeutic agents
WO2015138992A1 (en) 2014-03-14 2015-09-17 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
US20170224730A1 (en) 2014-06-10 2017-08-10 Institute For Myeloma & Bone Cancer Research Anti-cancer effects of proteasome inhibitors in combination with glucocorticoids, arsenic containing compounds, and ascorbic acid
GB201414806D0 (en) 2014-08-20 2014-10-01 Ucl Business Plc Cyclosporin conjugates
US10413558B2 (en) 2014-10-17 2019-09-17 Targeted Therapies Research And Consulting Center Sprl Multi-ingredient pharmaceutical composition for use in cancer therapy
CN104352566A (zh) 2014-10-21 2015-02-18 河南牧翔动物药业有限公司 一种水包油型复方金霉素纳米乳
JP6439931B2 (ja) 2015-02-26 2018-12-19 大日本印刷株式会社 吸着搬送装置および吸着搬送方法
US9844540B2 (en) 2015-10-06 2017-12-19 Redhill Biopharma Ltd. Combination therapies for treating cancer
CN105884633B (zh) * 2016-05-07 2017-12-26 浙江大学 一种四环素硬脂酸嫁接物及其制备和应用
CA3033105A1 (en) 2016-08-11 2018-02-15 The Council Of The Queensland Institute Of Medical Research Immune-modulating compounds
CN106511317A (zh) 2016-12-13 2017-03-22 浙江中同科技有限公司 一种掩味克拉霉素颗粒的制备方法
WO2018136598A1 (en) 2017-01-18 2018-07-26 Evelo Biosciences, Inc. Methods of treating cancer
US20200121739A1 (en) 2017-01-18 2020-04-23 Evelo Biosciences, Inc. Bacteria for treating cancer
CA3060510A1 (en) 2017-04-21 2018-10-25 Lunella Biotech, Inc. Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
US11229657B2 (en) 2017-04-21 2022-01-25 Lunella Biotech, Inc. Targeting hypoxic cancer stem cells (CSCs) with doxycycline: implications for improving anti-angiogenic therapy
WO2018202910A1 (en) 2017-05-05 2018-11-08 Fondazione Istituto Italiano Di Tecnologia Combination of antibiotic and bcl-2 inhibitor and uses thereof
BR112019024264A2 (pt) 2017-05-19 2020-06-02 Lunella Biotech, Inc. Antimitoscinas: inibidores direcionados da biogênese mitoconcrial para erradicação de células-tronco de câncer
US20200255902A1 (en) 2017-05-19 2020-08-13 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
WO2018218242A1 (en) 2017-05-26 2018-11-29 Epicentrx, Inc. Methods and compositions for combination therapy
RU2020120686A (ru) 2017-11-24 2021-12-24 Лунелла Байотек, Инк. Соединения производных трифенилфосфония для эрадикации раковых стволовых клеток
US11559527B2 (en) 2017-12-20 2023-01-24 Lunella Biotech, Inc. Targeting mitochondrial fission through mDIVI-1 derivatives

Also Published As

Publication number Publication date
US11865130B2 (en) 2024-01-09
RU2019142102A (ru) 2021-06-21
NZ760422A (en) 2023-11-24
EP3624840A4 (en) 2021-03-10
ZA201907654B (en) 2022-07-27
WO2018213751A1 (en) 2018-11-22
US20220072020A1 (en) 2022-03-10
RU2019142102A3 (pt) 2021-06-21
CU20190092A7 (es) 2020-10-20
PE20200605A1 (es) 2020-03-10
JP6938682B2 (ja) 2021-09-22
ZA202202712B (en) 2023-11-29
CR20190524A (es) 2020-01-10
ECSP19082194A (es) 2019-11-30
ZA202102509B (en) 2023-03-29
IL270598B (en) 2022-04-01
CL2019003283A1 (es) 2020-05-04
CO2019012888A2 (es) 2020-05-15
JP2020527127A (ja) 2020-09-03
AU2018270129A1 (en) 2020-01-16
AU2018270129B2 (en) 2021-01-07
DOP2019000294A (es) 2020-02-16
EP3624840A1 (en) 2020-03-25
US20200179424A1 (en) 2020-06-11
CA3063717C (en) 2021-08-24
CA3063717A1 (en) 2018-11-22
US11160821B2 (en) 2021-11-02
KR20200010343A (ko) 2020-01-30
CN111315400A (zh) 2020-06-19
MX2019013735A (es) 2020-01-15

Similar Documents

Publication Publication Date Title
BR112019024264A2 (pt) Antimitoscinas: inibidores direcionados da biogênese mitoconcrial para erradicação de células-tronco de câncer
ECSP19052302A (es) Derivados de benzooxazol como inmunomoduladores
CL2020002019A1 (es) Composiciones para modular la expresión de c9orf72. (divisional solicitud 201803582)
BR112015026307A2 (pt) heterociclo bicíclicos como inibidores de fgfr
BR112019005305A2 (pt) compostos espirocíclicos
BR112017017727A2 (pt) heterociclos bicíclicos como inibidores de fgfr4
BR112017017610A2 (pt) composto, composição farmacêutica, método de tratamento, método de diagnóstico, método de modulação da atividade
CR20180374A (es) Compuestos heterocíclicos como inmunomoduladores
BR112018004620A2 (pt) moduladores da expressão de kras
BR112015032595A2 (pt) inibidores de ido
BR112014021498A2 (pt) composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado
BR112014030812A2 (pt) "compostos tricíclicos substituídos como inibidores de fgfr, seus usos, composição farmacêutica e método para inibir uma enzima fgfr"
BR112014030386A8 (pt) Compostos e composições para modular a atividade de egfr
BR112016003201A2 (pt) inibidores de grp94 seletivos e usos dos mesmos
BR112018072545A2 (pt) inibidores da arginase e suas aplicações terapêuticas
BR112018013063A2 (pt) combinação terapêutica inibidora de bromodomínio e proteína extra-terminal
BR112019024566A2 (pt) inibidores de pirazol magl
BR112017025698A2 (pt) composições e métodos para inibir a expressão do gene de hif2alfa
BR112016024421A2 (pt) composição farmacêutica, cápsula e uso da composição farmacêutica
BR112022021690A2 (pt) Anticorpos de cadeia pesada multispecíficos com regiões constantes de cadeia pesada modificadas
CO2022000481A2 (es) Inhibidores de enzimas
ECSP19073204A (es) Mitorriboscinas: compuestos terapéuticos basados en mitocondrias que fijan como objetivo células cancerosas, bacterias y levaduras patógenas
BR112019018615A2 (pt) compostos antimicrobianos, composições e usos dos mesmos
BR112019021300A8 (pt) Composições de fragrâncias e produtos com efeitos de melhora do humor
ECSP20023626A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]